Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
LPD-824
N-Pyrrolidyllysergamide (LPD-824), also known as lysergic acid pyrrolidide (LA-Pyr), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the N,N-diethylamide moiety has been cyclized into an N,N-pyrrolidide ring.
The drug has been reported to have mild and relatively short-lasting LSD-like effects in humans at an oral dose of 800 μg equivalent to one-tenth this amount of LSD (i.e., 80 μg). Based on different clinical studies, it is estimated to be 5 to 10% as potent as LSD in humans. Its duration was shorter than that of LSD, lasting around 5 hours as opposed to 7 hours in the case of LSD. The drug produced nausea at small doses in humans, which was dose-limiting in terms of evaluating its effects.
LPD-824 is known to be a serotonin receptor modulator, including of the serotonin 5-HT2A receptor, where it acted as a partial agonist with about 17-fold lower potency than LSD but an efficacy slightly higher than that of LSD in terms of phosphatidylinositol (PI) hydrolysis. It also showed affinities for the serotonin 5-HT2C and 5-HT1A receptors similar to those of LSD.
It had about 5 to 10% of the potency of LSD in preclinical studies with animals, for instance in terms of serotonin antagonism in the rat uterus and hyperthermia in rabbits. It is described as a very strong hypotensive agent in animals. In subsequent rodent drug discrimination tests, LPD-824 fully substituted for LSD, albeit with only about 16 to 25% of the potency.
LPD-824 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.
LPD-824 is not a controlled substance in Canada as of 2025.
LPD-824 is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Hub AI
LPD-824 AI simulator
(@LPD-824_simulator)
LPD-824
N-Pyrrolidyllysergamide (LPD-824), also known as lysergic acid pyrrolidide (LA-Pyr), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the N,N-diethylamide moiety has been cyclized into an N,N-pyrrolidide ring.
The drug has been reported to have mild and relatively short-lasting LSD-like effects in humans at an oral dose of 800 μg equivalent to one-tenth this amount of LSD (i.e., 80 μg). Based on different clinical studies, it is estimated to be 5 to 10% as potent as LSD in humans. Its duration was shorter than that of LSD, lasting around 5 hours as opposed to 7 hours in the case of LSD. The drug produced nausea at small doses in humans, which was dose-limiting in terms of evaluating its effects.
LPD-824 is known to be a serotonin receptor modulator, including of the serotonin 5-HT2A receptor, where it acted as a partial agonist with about 17-fold lower potency than LSD but an efficacy slightly higher than that of LSD in terms of phosphatidylinositol (PI) hydrolysis. It also showed affinities for the serotonin 5-HT2C and 5-HT1A receptors similar to those of LSD.
It had about 5 to 10% of the potency of LSD in preclinical studies with animals, for instance in terms of serotonin antagonism in the rat uterus and hyperthermia in rabbits. It is described as a very strong hypotensive agent in animals. In subsequent rodent drug discrimination tests, LPD-824 fully substituted for LSD, albeit with only about 16 to 25% of the potency.
LPD-824 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.
LPD-824 is not a controlled substance in Canada as of 2025.
LPD-824 is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.